Understanding Gastric Cancer Spread Using MMR Status
Part of Cancer clinical trials.
This study looks at how a specific genetic marker (called MMR status) helps predict whether gastric cancer has spread to nearby lymph nodes. The research uses tissue samples from patients who had surgery or a minimally invasive procedure to remove early gastric cancers, and aims to improve how doctors assess cancer spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had gastric (stomach) cancer or cancer at the junction between your esophagus and stomach that was treated with surgery or an endoscopic procedure (ESD) at Zhongshan Hospital in Shanghai
- Your cancer was confirmed as adenocarcinoma (a common type of stomach cancer) by pathology
- You did not receive chemotherapy, radiation, immunotherapy, or other cancer treatments before your surgery or ESD procedure
- Complete pathology reports are available that clearly show lymphatic invasion status and lymph node involvement
- Your MMR status (a genetic marker) has been tested and is clearly determined
- You do not have another cancer diagnosis that would interfere with understanding where your gastric cancer has spread
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery can help people with a specific type of stomach cancer (dMMR/MSI-H) that can be removed. It aims to see how well the immune system responds and if the tumor shrinks.
This trial looks at how stomach cancer spreads to lymph nodes and other tissues behind the stomach during surgery. It may help doctors understand which patients need more extensive surgery.
This study looks at where cancer spreads in the short stomach area after total stomach removal surgery. It aims to understand lymph node and tumor deposits better to help guide future treatment decisions.
This study looks at how esophageal (or esophagus-stomach junction) cancer spreads to nearby lymph nodes. Results may help doctors understand where cancer cells are likely to be, potentially improving future surgery planning.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
This study tests if artificial intelligence can predict whether early-stage stomach cancer has spread to lymph nodes. It also evaluates how well doctors assess the cancer. If the technology works, it could help guide treatment decisions.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.